SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Orphan drug pricing may warrant a competition law investigation
0 references·3 citing·7 second hop
Orphan drug pricing may warrant a competition law investigation (2010)Orphan drug pricing may warrant a competi…Unintended effects of orphan product designation for rare neurological diseases (2012)Unintended effects of orphan …The Prevalence and Cost of Unapproved Uses of Top-Selling Orphan Drugs (2012)The Prevalence and Cost of Un…Drugs for Rare Diseases: Influence of Orphan Designation Status on Price (2011)Drugs for Rare Diseases: Infl…Orphan drugs and the NHS: should we value rarity? (2005)A journey of hope: lessons learned from studies on rare diseases and orphan drugs (2006)The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity? (2009)Global Spending on Orphan Drugs in France, Germany, the UK, Italy and Spain during 2007 (2010)Does orphan drug legislation really answer the needs of patients? (2008)Balancing Innovation, Access, and Profits — Market Exclusivity for Biologics (2009)The Orphan Drug Act (2015)
this work references cited by second hop

References

No references inside the corpus for this window.

Cited by

  • 2011Drugs for Rare Diseases: Influence of Orphan Designation Status on Price51 cited
  • 2012The Prevalence and Cost of Unapproved Uses of Top-Selling Orphan Drugs51 cited
  • 2012Unintended effects of orphan product designation for rare neurological diseases49 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work